Loading...
XKRX
086900
Market cap574mUSD
Dec 05, Last price  
127,100.00KRW
1D
0.39%
1Q
4.61%
Jan 2017
-64.36%
IPO
-19.30%
Name

Medy Tox Inc

Chart & Performance

D1W1MN
XKRX:086900 chart
P/E
49.91
P/S
3.70
EPS
2,546.47
Div Yield, %
Shrs. gr., 5y
0.78%
Rev. gr., 5y
2.12%
Revenues
228.62b
+3.39%
36,262,446,94039,141,030,12075,892,308,00088,505,437,514133,255,671,034181,239,191,116205,444,934,515205,900,275,787140,827,514,747184,869,547,955195,096,220,132221,120,682,590228,621,969,000
Net income
16.95b
+73.81%
15,436,739,78014,303,536,78043,627,867,04042,292,784,52859,231,019,51570,106,132,63769,963,675,93326,205,603,001-29,576,742,63694,153,921,07037,009,995,3709,755,098,73016,954,995,000
CFO
36.56b
+170.36%
14,779,384,52016,596,271,730105,379,387,53023,259,440,53653,443,912,35554,655,924,75453,462,056,56131,976,962,33925,746,780,92116,681,715,09924,135,315,71813,521,518,66036,556,164,000
Dividend
Sep 26, 2023952.38098 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hyaluronic acid filler products comprising Neuramis and Potenfill that are tissue recovering biomaterials. In addition, it provides various medical devices, such as ComfortDual and Recell Ice for tissue coagulation by using high-frequency current; Neurajet Plus to assist injecting other pharmaceuticals; Carewave for improving erectile dysfunction by using low-intensity shock wave generated from the electromagnetic method; and Careveam for treating skin ailment by using ultraviolet light. Further, the company offers Neurakin cream for acute eczema, contact dermatitis, atopic dermatitis, chronic eczema, rosacea dermatitis, perioral dermatitis, herpes zoster, and acne vulgaris. It also exports its products to approximately 60 countries, including Japan, Thailand, and Brazil. Medytox, Inc. has partnership with Dyadic International, Inc. to develop vaccines against COVID-19 variants. The company was founded in 2000 and is headquartered in Cheongju, South Korea.
IPO date
Jan 16, 2009
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT